medicamento priligy estudios clinicos NIOSH response NIOSH has determined that teratogenicity or other developmental toxicity after exposure to osimertinib were observed at doses higher than the maximum recommended human dose and reproductive effects at doses lower than the maximum recommended human doses were equivocal
Edgar Visser 
Fanny Mulder 
Lucas De Jong
medicamento priligy estudios clinicos NIOSH response NIOSH has determined that teratogenicity or other developmental toxicity after exposure to osimertinib were observed at doses higher than the maximum recommended human dose and reproductive effects at doses lower than the maximum recommended human doses were equivocal